Total submissions: 1
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Victorian Clinical Genetics Services, |
RCV002471843 | SCV002766832 | likely pathogenic | Developmental and epileptic encephalopathy, 57 | 2022-03-31 | criteria provided, single submitter | clinical testing | Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Likely pathogenic. Following criteria are met: 0103 - Both loss of function and gain of function are known mechanisms of disease for this gene. Gain of function, loss of function, change of function, and the possibility of a dominant negative mechanism, have all been reported for pathogenic KCNT2 variants in patients with early-onset epileptic encephalopathies, including epilepsy of infancy with migrating focal seizures (PMIDs: 29069600, 29740868, 32038177). (I) 0107 - This gene is associated with autosomal dominant disease. (I) 0201 - Variant is predicted to cause nonsense-mediated decay (NMD) and loss of protein (premature termination codon is located at least 54 nucleotides upstream of the final exon-exon junction). (SP) 0251 - This variant is heterozygous. (I) 0301 - Variant is absent from gnomAD (both v2 and v3). (SP) 0703 - Other variants comparable to the one identified in this case have moderate previous evidence for pathogenicity. Four other NMD-predicted variants have previously been classified as pathogenic or likely pathogenic (ClinVar, PMID: 32038177). (SP) 0807 - This variant has no previous evidence of pathogenicity. (I) 0905 - No published segregation evidence has been identified for this variant. (I) 1007 - No published functional evidence has been identified for this variant. (I) 1205 - This variant has been shown to be maternally inherited (by trio analysis). (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign |